ArticleCureus2026
Blood Safety: The Madhya Pradesh Centralized Nucleic Acid Testing (NAT) Model for Blood Donor Screening.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEnsuring safe blood transfusion is a public health priority in India, where reliance on serological screening alone may miss early infections. Centralized nucleic acid testing (NAT) offers an opportunity to strengthen blood safety through advanced molecular diagnostics.
aimThis study aimed to highlight the successful implementation of the Madhya Pradesh centralized NAT hub and spoke model for enhancing blood transfusion safety.
methodsThe current project was implemented through a public-private partnership (PPP) using a hub-and-spoke model. To assess its merit, a retrospective analysis of program data was conducted between January 2023 and September 2024 across Madhya Pradesh, India. Deidentified records from 24 satellite blood centers, including district hospitals and specialized blood banks, were processed at central hubs in Indore and Bhopal, which used the Roche cobas® TaqScreen MPX test (version 2.0). Operational challenges and performance indicators were reviewed.
resultsA total of 158,493 seronegative samples were processed, of which 943 (1 in 168) were NAT-reactive and would have been missed by routine serological screening, potentially preventing 2829 transfusion-transmitted infections. The program maintained a 48-hour turnaround time from sample collection to reporting. Operational challenges, such as standardization of sample handling, maintenance of the cold chain during transport, and high testing volumes, were successfully addressed through rigorous protocols and training.
conclusionThe Madhya Pradesh centralized NAT model is feasible, effective, and efficient, demonstrating its potential to reform blood safety in India. This model may serve as a replicable framework for other developing countries facing similar challenges in transfusion medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.